- Home
- PTLO vs FBRX Comparison
PTLO vs FBRX Comparison
Compare PTLO & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTLO | FBRX |
|---|---|---|
| Founded | 1963 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.0M | 367.4M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PTLO | FBRX |
|---|---|---|
| Price | $5.51 | $28.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $8.06 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 1.5M | 205.9K |
| Earning Date | 05-28-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $732,066,000.00 | $36,000.00 |
| Revenue This Year | $9.71 | N/A |
| Revenue Next Year | $6.20 | N/A |
| P/E Ratio | $19.56 | ★ N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $4.41 | $4.91 |
| 52 Week High | $14.47 | $35.62 |
Technical Indicators
Market Signals| Indicator | PTLO | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 47.69 |
| Support Level | $5.34 | $26.58 |
| Resistance Level | $6.12 | $32.12 |
| Average True Range (ATR) | 0.33 | 2.57 |
| MACD | -0.06 | -0.40 |
| Stochastic Oscillator | 36.27 | 34.47 |
Price Performance
Historical ComparisonAbout PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).